INSULIN RESISTANCE AND DISEASES OF THE INTERNAL ORGANS

Download full text PDF
Issue: 
9
Year: 
2017

Professor A. Verbovoy, MD; L. Sharonova, Candidate of Medical Sciences; A. Pashentseva, Candidate of Medical Sciences; Professor N. Verbovaya, MD; Professor R. Galkin, MD Samara State Medical University

The paper considers the mechanism of insulin resistance and its impact on the development of different diseases (type 2 diabetes mellitus and its complications, cardiovascular diseases, nonalcoholic fatty liver disease, polycystic ovary syndrome, and gout), as well as current methods for correcting insulin resistance
Keywords: 
endocrinology
insulin resistance
diabetes mellitus
type 2 diabetes mellitus
cardiovascular diseases
nonalcoholic fatty liver disease
polycystic ovary syndrome
and gout

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ozhirenie i izbytochnyj ves. Informatsionnyj bjulleten'. Ijun' 2016 g. http://www.who.int/mediacentre/factsheets/fs311/ru/
  2. Kvitkova L.V., Elenskaja T.S., Blagoveschenskaja O.P. Insulino- rezistentnost' i faktory, ee opredeljajuschie // Sibirskij med. zhurn. – 2008; 5: 12–6.
  3. Shishko E.I., Mohort T.V., Mohort E.G. Narushenija endokrinnoj reguljatsii pri zabolevanijah, svjazannyh s insulinorezistentnost'ju // Lechebnoe delo. – 2016; 5: 76–81.
  4. Shagalova N.Ja. Insulinorezistentnost' – pol'za ili vred? // Sovremennye problemy nauki i obrazovanija. – 2016; 2: 89.
  5. Samuel V., Petersen K., Shulman G. Lipid-induced insulin resistance: unravelling the mechanism // Lancet. – 2010; 375 (9733): 2267–77.
  6. Bosello O., Zamboni M. Visceral obesity and metabolic syndrome // Obes. Rev. – 2000; 1 (1): 47–56.
  7. Butrova S.A. Metabolicheskij sindrom: patogenez, klinika, diagnostika, podhody k lecheniju // Ros. med. zhurn. – 2001; 2: 21.
  8. Butrova S.A., Ershova E.V., Il'in A.V. Adipotsitokiny: rezistin i faktor nekroza opuholi-α u muzhchin s abdominal'nym ozhireniem // Ozhirenie i metabolizm. – 2007; 4: 30–3.
  9. Baratta R., Amato S., Degano C. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies // J. Clin. Endocrinol. Metab. – 2004; 89 (6): 2665–71.
  10. von Eynatten M., Hamann A., Twardella D. et al. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease // Clin. Chem. – 2006; 52 (5): 853–9.
  11. Yang R., Barouch L. Leptin signaling and obesity: cardiovascular consequences // Circ. Res. – 2007; 101 (6): 545–59.
  12. Chubrieva S.Ju., Gluhov N.V., Zajchik A.M. Zhirovaja tkan' kak endokrinnyj reguljator (obzor literatury) // Vestn. SPbGU. Serija 11. Meditsina. – 2008; 1: 32–44.
  13. Peter J., Havel J. et al. Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin // Am. J. Physiol. Endocrinol. Metab. – 2000; 278: 114.
  14. Pashentseva A.V. Rol' leptina i rezistina v razvitii insulinorezistentnosti u bol'nyh saharnym diabetom 2-go tipa. Avtoref. dis. … kand. med.nauk. Samara, 2012; 23 s.
  15. Vorozhtsova E.I. Rol' defitsita testosterona v razvitii insulinorezistentnosti u muzhchin s saharnym diabetom 2 tipa. Avtoref. dis. … kand. med.nauk. Samara, 2013; 22 s.
  16. Osegbe I., Okpara H., Azinge E. Relationship between serum leptin and insulin resistance among obese Nigerian women // Ann. Afr. Med. – 2016; 15 (1): 14–9.
  17. Kadykova O.I. Rol' gormonov zhirovoj tkani v geneze insulinorezistentnosti u bol'nyh gipertonicheskoj bolezn'ju i saharnym diabetom 2-go tipa // Mezhd. med. zhurn. – 2012; 2: 54–7.
  18. Kirillova O.O., Vorozhko I.V., Gapparova K.M. i dr. Adipokiny i metabolizm kljuchevyh pischevyh veschestv u bol'nyh s ozhireniem // Ter. arh. – 2014; 1: 45–8.
  19. Verbovoj A.F. Gipotireoz: klinicheskaja kartina i lechenie // Vrach. – 2015; 10: 21–4.
  20. Anderson J., May H., Horne B. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population // Am. J. Cardiol. – 2010; 106 (70): 963–8.
  21. Pittas A., Lau J., Hu F. et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis // J. Clin. Endocrinol. Metab. – 2007; 92 (6): 2017–29.
  22. Penckofer S., Kouba J., Wallis D. et al. Vitamin D and diabetes let the sunshine in // Diabet. Educ. – 2008; 34: 939.
  23. Paula R., Silva A., Hall J. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration // Hypertension. – 2004; 43 (1): 41–7.
  24. Feliciano Pereira P., Eloiza Priore S., Bressan J. Aldosterone: a cardiometabolic risk hormone? // Nutr. Hosp. – 2014; 30: 1191–202.
  25. Vatutin N.T., Shevelek A.N., Degtjareva A.E. Al'dosteron i ozhirenie: gde iskat' kljuch k terapii? // Arhiv' vnutrennej meditsiny. – 2016; 4 (30): 21–9.
  26. Majorov A.Ju., Urbanova K.A., Galstjan G.R. Metody kolichestvennoj otsenki insulinorezistentnosti // Ozhirenie i metabolizm. – 2009; 2: 19–23.
  27. Osina A.S. Otsenka vzaimosvjazi insulinorezistentnosti i endotelial'noj disfunktsii u bol'nyh SD 2-go tipa. Avtoref. dis. … kand. med. nauk. Samara, 2010; 21 s.
  28. Bondar' I.A., Shabel'nikova O.Ju. Rol' insulinorezistentnosti v razvitii kardiovaskuljarnoj formy diabeticheskoj avtonomnoj nejropatii u bol'nyh saharnym diabetom 2-go tipa // Sibirskij med. zhurn. – 2009; 24 (1): 13–6.
  29. Erohina E.N. Rol' insulinorezistentnosti v razvitii makrososudistyh oslozhnenij saharnogo diabeta 2-go tipa i puti ee korrektsii. Avtoref. dis. … kand. med.nauk. M., 2007; 25 s.
  30. An D., Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy // Am. J. Physiol. Heart Circ. Physiol. – 2006; 291: 1489–506.
  31. Korneeva O.N., Drapkina O.M. Patogeneticheskie vzaimosvjazi arterial'noj gipertenzii i insulinorezistentnosti // Ros. kardiol. zhurn. – 2006; 5: 100–3.
  32. Kendall M., Sobel B., Coulston A. The insulin resistance syndrome and coronary artery disease // Coron. Artery Dis. – 2003; 14 (4): 335–48.
  33. Kvitkova L.V., Elenskaja T.S., Blagoveschenskaja O.P. i dr. Vlijanie insulinorezistentnosti i narushenij uglevodnogo obmena na techenie ostrogo perioda infarkta miokarda // Probl. endokrinol. – 2011; 2: 9–13.
  34. Sinha D., Ahmed S., Baneerjee A. et al. Significance of an index of insulin resistance in non-diabetic patients with impaired fasting glucose with acute myocardial infarction and its correlation to short term outcome // Indian Heart J. – 2009; 61 (1): 40–3.
  35. Tamita K., Yamamuro A., Kaji S. et al. Insulin resistance adds prognostic information on long-term clinical outcome after acute myocardial infarction among Japanese patients with and without glucose intolerance // Circulation. – 2006; 114: 743.
  36. Elenskaja T.S., Blagoveschenskaja O.P., Kvitkova L.V. i dr. Rol' insulinorezistentnosti v razvitii serdechno-sosudistyh sobytij postinfarktnogo perioda // Kardiologija v Belorussii. – 2011; 5: 104.
  37. Gruzdeva O.V., Karetnikova V.N., Uchasova E.G. i dr. Insulino- rezistentnost' i risk neblagoprijatnogo ishoda cherez 1 god posle perenesennogo infarkta miokarda // Vrach. – 2015; 12: 30–4.
  38. Kvitkova L.V., Elenskaja T.S., Blagoveschenskaja O.P. i dr. Evoljutsija insulinorezistentnosti na primere bol'nyh infarktom miokarda s pod'emom segmenta ST // Sibirskij med. zhurn. – 2011; 26 (4–2): 161–5.
  39. Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogol'noj zhirovoj bolezni pecheni v Rossii. Rezul'taty otkrytogo mnogotsentrovogo prospektivnogo issledovanija-nabljudenija DIREG L 01903 // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2014; 4: 32–8.
  40. Balukova E.V., Baryshnikova N.V., Belousova L.N. Nealkogol'naja zhirovaja bolezn' pecheni: sovremennoe sostojanie problemy // Farmateka. – 2016; 2: 63–8.
  41. Chesnokova L.V., Petrov I.M., Troshina I.A. i dr. Insulino- rezistentnost', aterogennye narushenija i fibroz pecheni u bol'nyh s metabolicheskim sindromom // Ozhirenie i metabolizm. – 2014; 2: 17–23.
  42. Chesnokova L.V., Petrov I.M., Medvedeva I.V. Funktsija endotelija i soderzhanie adipokinov u patsientov s nealkogol'noj zhirovoj bolezn'ju pecheni // Klin. perspektivy gastroenterol., gepatol. – 2014; 6: 18–24.
  43. Zaharova N.N., Dvorjanskij S.A. Sindrom polikistoznyh jaichnikov // Vjatskij med. vestn. – 2010; 2: 3–8.
  44. Andreeva E.N., Pischulin A.A., Akmaev R.I. i dr. Sravnitel'noe izuchenie vlijanija insulinorezistentnosti na androgennuju aktivnost' nadpochechnikov i jaichnikov u zhenschin rannego reproduktivnogo vozrasta s sindromom polikistoza jaichnikov // Ozhirenie i metabolizm. – 2010; 2: 29–35.
  45. Zakirova V.B. Metabolicheskij sindrom, giperurikemija i podagra // Prakticheskaja meditsina.– 2010; 44: 27–31.
  46. Barskova V.G., Eliseev M.S., Nasonov E.L. i dr. Sindrom insulinorezistentnosti u bol'nyh podagroj i ego vlijanie na formirovanie klinicheskih osobennostej bolezni // Ter. arh. – 2004; 5: 51–6.
  47. Mkrtumjan A.M., Birjukova E.V., Markina N.V. i dr. Parametry endotelial'noj funktsii i insulinorezistentnosti bol'nyh metabolicheskim sindromom do i posle snizhenija massy tela // Ozhirenie i metabolizm. – 2008; 1: 18–22.
  48. Demidova T.Ju. Etiopatogeneticheskaja rol' insulinorezistentnosti v razvitii metabolicheskih i sosudistyh narushenij pri saharnom diabete tipa 2 // Farmateka. – 2010; 16: 18–24.
  49. Petunina N.A., Kuzina I.A. Rol' gormonov zhirovoj tkani v razvitii oslozhnenij beremennosti u zhenschin s ozhireniem // Ozhirenie i metabolizm. – 2013; 1 (34): 3–8.
  50. Shestakova M.V., Breskina O.Ju. Insulinorezistentnost': patofiziologija, klinicheskie projavlenija, podhody k lecheniju // Consilium Medicum. – 2002; 10: 523–7.
  51. Shishkova V.N. Sovremennyj podhod k terapii saharnogo diabeta 2-go tipa – vlijanie na insulinorezistentnost' // Farmateka. – 2011; 3: 42–9.
  52. Drapkina O.M., Korneeva O.N. Fiksirovannaja kombinatsija amlodipina i lizinoprila: preimuschestva primenenija pri metabolicheskom sindrome // Vrach. – 2012; 12: 42–5.
  53. Vitale S., Mercuro G., Castiglioni C. et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome // Cardiovasc. Diabetol. – 2005; 4: 6–11.
  54. Chazova I.E., Mychka V.B. Novye vozmozhnosti v lechenii bol'nyh s metabolicheskim sindromom (rezul'taty issledovanija ALMAZ) // Sistemnye gipertenzii. – 2006; 2: 14–7.
  55. Dedov I.I. Rezul'taty issledovanija ALMAZ: vpervye pokazano, chto moksonidin povyshaet chuvstvitel'nost' k insulinu u bol'nyh arterial'noj gipertenziej s ozhireniem // Ozhirenie i metabolizm. – 2006; 1: 50–1.